<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010391533</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010391533</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of the Efficacy and Tolerance of a Topical Gel With 4% Quassia Extract in the Treatment of Rosacea</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ferrari</surname><given-names>Alicia</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Diehl</surname><given-names>Christian</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-0091270010391533">Universidad Nacional de Córdoba, Argentina</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0091270010391533">Christian Diehl, MD, Domingo Uriarte 192, B Lomas de San Martin, Cordoba 5008, Argentina; e-mail: <email>chdiehl@hotmail.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>84</fpage>
<lpage>88</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>8</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>10</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p><bold>Background</bold>: There are various treatment options available for rosacea, depending on the subtype, but treatment is still generally unsatisfactory. Some studies have reported antiparasitic and anti-inflammatory properties of <italic>Quassia amara</italic>. <bold>Aim</bold>: To check the efficacy and safety of a topical gel with 4% <italic>Quassia amara</italic> extract in the treatment of various grades of rosacea. <bold>Methods</bold>: A group of 30 patients with various grades of rosacea (I-IV) were investigated in a single-center, open-label study. They were treated with a topical gel with 4% <italic>Quassia amara</italic> extract for 6 weeks. Response was evaluated by the flushing, erythema, telangiectasia, papules, and pustules scores. At the end of therapy, overall improvement, safety, and tolerability were assessed. <bold>Results</bold>: Twenty-seven of 30 patients (90%) completed the study. The treatment resulted to be very effective, and the results achieved were in line with those published with topical metronidazole and azelaic acid. Safety and tolerability were excellent. <bold>Conclusion</bold>: Topical quassia extract could be a new, efficient, and safe weapon in the armamentarium for the management of rosacea.</p>
</abstract>
<kwd-group>
<kwd>Clinical trial</kwd>
<kwd>erythema</kwd>
<kwd>flushing</kwd>
<kwd>papules</kwd>
<kwd>pustules</kwd>
<kwd>quassia</kwd>
<kwd>rosacea</kwd>
<kwd>telangiectasia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Rosacea is a common chronic skin disorder observed primarily among patients with Fitzpatrick I &amp; II skin types. In general, clinical observation is sufficient to diagnose conditions when the patient presents on the face, neck, chest, or ears with flushing, persistent erythema, telangiectasias, eruption of inflamed papules, pustules, and hypertrophy with fibrosis<sup><xref ref-type="bibr" rid="bibr1-0091270010391533">1</xref></sup> of the sebaceous glands of the nose.</p>
<p>The exact cause of rosacea remains unknown, with no known cure available. Extrinsic and intrinsic factors can exacerbate conditions and consist of a series of vascular disorders with structural alterations of cutaneous vasculature,<sup><xref ref-type="bibr" rid="bibr2-0091270010391533">2</xref></sup> compromised vascular integrity and increased angiogenesis,<sup><xref ref-type="bibr" rid="bibr3-0091270010391533">3</xref></sup> and expression of angiogenesis factors (in particular vascular endothelial growth factor).<sup><xref ref-type="bibr" rid="bibr4-0091270010391533">4</xref></sup> <italic>Demodex folliculorum</italic>, a species of face mite found in the hair follicle, may also play a key role in the onset and maintenance of the disorder. Recent focus has been given to the important mechanisms of matrix degradation<sup><xref ref-type="bibr" rid="bibr5-0091270010391533">5</xref></sup> and abnormal generation of reactive oxygen species, provoking inflammation and vascular abnormalities.<sup><xref ref-type="bibr" rid="bibr6-0091270010391533">6</xref></sup></p>
<p>The standard course of treatment remains the topical prescription agents metronidazole and azelaic acid, which may be combined with adjunctive therapies, including oral antibiotics. <italic>Quassia amara</italic> is a tropical plant species widely used in folk medicine for a variety of indications, such as parasitic and digestive diseases. Its topical use is also frequently mentioned among popular indications.</p>
<p><italic>Quassia amara</italic> features a shrub or small tree originating in South America. It contains high levels of active phytochemicals, including the triterpenoid quassinoids. Various biological activities are described in the literature, including antiparasitic activities against pediculosis<sup><xref ref-type="bibr" rid="bibr7-0091270010391533">7</xref>,<xref ref-type="bibr" rid="bibr8-0091270010391533">8</xref></sup> and anti-inflammatory properties.<sup><xref ref-type="bibr" rid="bibr9-0091270010391533">9</xref>,<xref ref-type="bibr" rid="bibr10-0091270010391533">10</xref></sup> Because of these previously disclosed properties, we have successfully used a hydroglycolic extract of quassia on patients with rosacea. Initial patient satisfaction prompted the decision to conduct a preliminary clinical trial with this topical preparation.</p>
<sec id="section1-0091270010391533" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section2-0091270010391533">
<title>Study Design</title>
<p>The study comprised 30 patients receiving a 4% quassia topical gel. The activity of the test gel was evaluated by comparing each patient’s condition at baseline with his or her condition at the end of the study. All patients provided informed consent before the beginning of the trial and were free to terminate their participation at any time. The Declaration of Helsinki and its revisions were followed.</p>
</sec>
<sec id="section3-0091270010391533">
<title>Study Population</title>
<p>Male and female (not pregnant or nursing) patients enrolled for the study had grade I to IV rosacea (standard classification of rosacea<sup><xref ref-type="bibr" rid="bibr1-0091270010391533">1</xref></sup>) and were at least 18 years of age. Exclusion criteria included known allergies to any component of the formula, previous history of skin cancer (melanoma or nonmelanoma) in affected areas, patient participation in other clinical studies within 3 months before this study, or patients whose mental condition did not permit good compliance.</p>
</sec>
<sec id="section4-0091270010391533">
<title>Study Protocol</title>
<p>To avoid any carryover effects from preceding therapy, there was a washout period of 4 weeks after topical and/or systemic treatment of rosacea. Patients treated with any systemic, topical, or cosmetic treatment that could influence the parameters of evaluation of the study were rejected.</p>
<p>Patients were directed to apply the study gel to affected areas in the morning and evening for 45 days, in quantities of approximately 0.05 mL/cm<sup>2</sup>. This product was delivered in the form of an aqueous gel containing 4% of a hydroglycolic extract of <italic>Quassia amara</italic> at 250% (wt/vol) standardized at 0.40% (wt/vol) of quassin. This gel also contained carbomer (0.8%) and xanthan gum (0.2%), along with a preservative system consisting of phenoxyethanol (0.12%) and benzyl alcohol (0.1%). Its viscosity was 50 000 Cps, and the pH was 5. No specific toxicological trial was performed on the standardized extract, given that <italic>Quassia amara</italic> possesses the status of “generally recognized as safe” by the US Food and Drug Administration.</p>
<p>At baseline, general patient data including sex, age, phototype (Fitzpatrick classification), grade of rosacea, time of onset and history, localization, and previous treatments were recorded. During the treatment phase, the therapeutic progress was assessed at 15-day intervals (after 15, 30, and 45 days). All evaluable patients who completed the study were considered in a global evaluation of the results achieved at the end of therapy.</p>
<p>Treatment efficacy was assessed by counting the number of inflammatory papules and pustules rated as 0, no papule/pustule; 1, number of papules/pustules &lt; 5; 2, number of papules/pustules &gt; 5 and &lt; 20; and 3, &gt;20 and rating the flushing (0, no flush; 1, intermittent flushing; 2, permanent flushing; 3, intense flushing), erythema (0, no erythema; 1, mild erythema; 2, moderate erythema; 3, severe erythema) (<xref ref-type="table" rid="table1-0091270010391533">Table I</xref>), and telangiectasia (0, no; 1, mild; 2, moderate; 3, severe). Each visit included an evaluation of local tolerance and local and systemic adverse events as determined by both patients and physician. At each visit, 2 photographs were taken in daylight.</p>
<table-wrap id="table1-0091270010391533" position="float">
<label>Table I</label>
<caption><p>Assessment of Overall Erythema Severity</p></caption>
<graphic alternate-form-of="table1-0091270010391533" xlink:href="10.1177_0091270010391533-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Numerical Score</th>
<th align="center">Rating</th>
<th align="center">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>Either no visible erythema or minimal residual erythema</td>
</tr>
<tr>
<td>1</td>
<td>Mild</td>
<td>Slight erythema, either centrofacial or generalized to whole face</td>
</tr>
<tr>
<td>2</td>
<td>Moderate</td>
<td>Pronounced erythema, either centrofacial or generalized to whole face</td>
</tr>
<tr>
<td>3</td>
<td>Severe</td>
<td>Severe erythema with a red to purple hue, either centrofacial or generalized to whole face</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>At the end of therapy, overall improvement was determined as complete remission, marked improvement (at least 3 parameters improved), moderate improvement (at least 2 parameters improved), no improvement, or deterioration. For evaluation, the latter 2 overall ratings were combined as “poor.”</p>
</sec>
</sec>
<sec id="section5-0091270010391533" sec-type="results">
<title>Results</title>
<sec id="section6-0091270010391533">
<title>Patient Characteristics</title>
<p>Study enrollment occurred from June 2009 to August 2009. Thirty patients were enrolled in the study. The patient baseline characteristics are presented in <xref ref-type="table" rid="table2-0091270010391533">Table II</xref>. The male/female ratio of enrolled patients was 20%/80%, their mean age was 50.3 years (range, 21-82 years), and the mean previous duration of rosacea was 4.73 years (range, 0.5-15 years). Approximately 33% of patients had received previous treatment for rosacea. The disposition of patients is summarized in <xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref>.</p>
<table-wrap id="table2-0091270010391533" position="float">
<label>Table II</label>
<caption>
<p>Patient Characteristics</p>
</caption>
<graphic alternate-form-of="table2-0091270010391533" xlink:href="10.1177_0091270010391533-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="center">No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female patients</td>
<td>6/24 (20%/80%)</td>
</tr>
<tr>
<td>Mean age, y</td>
<td>50.3 (range, 21-82)</td>
</tr>
<tr>
<td colspan="2">Phototype</td>
</tr>
<tr>
<td>II</td>
<td>2 (6.6%)</td>
</tr>
<tr>
<td>III</td>
<td>24 (80%)</td>
</tr>
<tr>
<td>IV</td>
<td>4 (13.3%)</td>
</tr>
<tr>
<td colspan="2">Grade (standard classification of rosacea, US National Rosacea Society)</td>
</tr>
<tr>
<td>I</td>
<td>5 (16.7%)</td>
</tr>
<tr>
<td>II</td>
<td>15 (50%)</td>
</tr>
<tr>
<td>III</td>
<td>5 (16.7%)</td>
</tr>
<tr>
<td>IV</td>
<td>5 (16.7%)</td>
</tr>
<tr>
<td>Mean previous duration of rosacea, y Localization</td>
<td>4.73 (range, 0.5-15)</td>
</tr>
<tr>
<td>Chin</td>
<td>21 (70%)</td>
</tr>
<tr>
<td>Cheeks</td>
<td>30 (100%)</td>
</tr>
<tr>
<td>Forehead</td>
<td>15 (50%)</td>
</tr>
<tr>
<td>Nose</td>
<td>23 (76.7%)</td>
</tr>
<tr>
<td>Rhinophyma</td>
<td>2 (6.7%)</td>
</tr>
<tr>
<td>Ocular</td>
<td>5 (16.7%)</td>
</tr>
<tr>
<td>Patients with previous rosacea therapy</td>
<td>10 (33.3%)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig1-0091270010391533" position="float">
<label>Figure 1.</label>
<caption><p>Evolution of mean scores of various parameters along the study.</p></caption>
<graphic xlink:href="10.1177_0091270010391533-fig1.tif"/>
</fig>
<p>Overall, 90% of patients completed the study, and the remaining 10% (3 patients) were lost to follow up, mainly due to the fact that the study took place during an epidemic of influenza. No patient was discontinued due to occurrence of adverse effects.</p>
</sec>
<sec id="section7-0091270010391533">
<title>Flushing</title>
<p>Patients experienced a continuous decline in mean flushing score throughout 6 weeks of treatment, from a mean of 1.41 ± 0.75 at baseline to a mean of 0.37 ± 0.49 at day 45, that is, a decrease in flushing score of 74% (<italic>P</italic> &lt; .001) (<xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref> and <xref ref-type="table" rid="table3-0091270010391533">Table III</xref>).</p>
<table-wrap id="table3-0091270010391533" position="float">
<label>Table III</label>
<caption>
<p>Mean ± SD Score of Various Parameters Along the Study</p>
</caption>
<graphic alternate-form-of="table3-0091270010391533" xlink:href="10.1177_0091270010391533-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Day 0</th>
<th align="center">Day 15</th>
<th align="center">Day 30</th>
<th align="center">Day 45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flushing</td>
<td>1.41 ± 0.75</td>
<td>1.26 ± 0.59<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.89 ± 0.42</td>
<td>0.37 ± 0.49<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
</tr>
<tr>
<td>Erythema</td>
<td>1.92 ± 1.00</td>
<td>1.41 ± 0.80<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>1.26 ± 0.66<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.85 ± 0.77<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
</tr>
<tr>
<td>Telangiectasia</td>
<td>1.70 ± 0.82</td>
<td>1.52 ± 0.75<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>1.30 ± 0.95<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.85 ± 0.77<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
</tr>
<tr>
<td>Papules</td>
<td>1.22 ± 1.15</td>
<td>0.70 ± 0.82<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.44 ± 0.58<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.19 ± 0.40<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
</tr>
<tr>
<td>Pustules</td>
<td>0.56 ± 0.70</td>
<td>0.30 ± 0.54<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.07 ± 0.27<sup><xref ref-type="table-fn" rid="table-fn1-0091270010391533"><italic>a</italic></xref></sup></td>
<td>0.00</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010391533">
<label>a</label>
<p><italic>P</italic> &lt; .001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0091270010391533">
<title>Erythema</title>
<p>The mean erythema score exhibited a continuous decline during this study, from a mean of 1.92 ± 1.00 at baseline to a mean of 0.85 ± 0.77 at day 45, a decrease in erythema score of 56% (<italic>P</italic> &lt; .001) (<xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref> and <xref ref-type="table" rid="table3-0091270010391533">Table III</xref>).</p>
</sec>
<sec id="section9-0091270010391533">
<title>Telangiectasia</title>
<p>The mean telangiectasia score showed a continuous decline throughout 6 weeks of treatment, from a mean of 1.70 ± 0.82 at baseline to a mean of 0.85 ± 0.77 at day 45, a decrease in telangiectasia score of 50% (<italic>P</italic> &lt; .001) (<xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref> and <xref ref-type="table" rid="table3-0091270010391533">Table III</xref>).</p>
</sec>
<sec id="section10-0091270010391533">
<title>Papules</title>
<p>Patients experienced a continuous decline in the mean papules score during this study, from a mean of 1.22 ± 1.15 at baseline to a mean of 0.19 ± 0.40 at day 45, a decrease in papules score of 84% (<italic>P</italic> &lt; .001) (<xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref> and <xref ref-type="table" rid="table3-0091270010391533">Table III</xref>).</p>
</sec>
<sec id="section11-0091270010391533">
<title>Pustules</title>
<p>The mean pustules score experienced a dramatic and continuous decline throughout 6 weeks of treatment, from a mean of 0.56 ± 0.70 at baseline to a mean of 0.00 at day 45, as shown in <xref ref-type="fig" rid="fig1-0091270010391533">Figure 1</xref> and <xref ref-type="table" rid="table3-0091270010391533">Table III</xref>. This shows a decrease in pustules score of 100% (<italic>P</italic> &lt; .001) during the study.</p>
</sec>
<sec id="section12-0091270010391533">
<title>Overall Improvement</title>
<p>An overall improvement occurred over time in this study. More than 37% of patients experienced excellent improvement or complete remission; 22% felt a marked improvement, nearly 30% a moderate improvement, and only 11% had no improvement throughout 6 weeks of treatment (<xref ref-type="table" rid="table4-0091270010391533">Table IV</xref> and <xref ref-type="fig" rid="fig2-0091270010391533">Figure 2</xref>).</p>
<table-wrap id="table4-0091270010391533" position="float">
<label>Table IV</label>
<caption>
<p>Overall Improvement at the End of the Therapy</p>
</caption>
<graphic alternate-form-of="table4-0091270010391533" xlink:href="10.1177_0091270010391533-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">No. of Patients</th>
<th align="center">%</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">No. of parameters improved</td>
</tr>
<tr>
<td> 1</td>
<td>3</td>
<td>11.1</td>
</tr>
<tr>
<td> 2</td>
<td>8</td>
<td>29.6</td>
</tr>
<tr>
<td> 3</td>
<td>6</td>
<td>22.2</td>
</tr>
<tr>
<td> 4</td>
<td>6</td>
<td>22.2</td>
</tr>
<tr>
<td> 5</td>
<td>4</td>
<td>14.8</td>
</tr>
<tr>
<td colspan="3">Improvement</td>
</tr>
<tr>
<td> No improvement</td>
<td>3</td>
<td>11.1</td>
</tr>
<tr>
<td> Moderate improvement</td>
<td>8</td>
<td>29.6</td>
</tr>
<tr>
<td> Marked improvement</td>
<td>6</td>
<td>22.2</td>
</tr>
<tr>
<td> Complete remission (4 or 5 parameters improved)</td>
<td>10</td>
<td>37.1</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig2-0091270010391533" position="float">
<label>Figure 2.</label>
<caption>
<p>Overall improvement at the end of therapy.</p>
</caption>
<graphic xlink:href="10.1177_0091270010391533-fig2.tif"/>
</fig>
<p>Comparatively, greater results were obtained in patients with severe grades of rosacea (all patients, except 1, with grades III or IV showed marked improvement or complete remission).</p>
</sec>
<sec id="section13-0091270010391533">
<title>Adverse Effects and Tolerance</title>
<p>No adverse effects such as itching, edema, burning, and stinging were reported during this study. The tolerance was excellent in all patients who completed the treatment.</p>
</sec>
</sec>
<sec id="section14-0091270010391533" sec-type="discussion">
<title>Discussion</title>
<p>To the best of our knowledge, this is the first clinical trial of topical quassia extract for the treatment of various grades of rosacea. This preliminary study demonstrates the safety and efficacy of 4% quassia extract gel for the treatment of all grades of rosacea. Patients experienced significant reductions in flushing, erythema, papules, pustules, and telangiectasia after 6 weeks of treatment. Improvements in global assessment of disease severity determined by the investigators also showed excellent results at the end of this study, and the patients experienced continuous improvements throughout the duration of the study.</p>
<p>The real efficacy of quassia extract may be explained not only by its antiparasitic action on <italic>Demodex folliculorum</italic> but also its strong anti-inflammatory and antioxidant effects. Verma et al<sup><xref ref-type="bibr" rid="bibr11-0091270010391533">11</xref></sup> have reported the potent inhibitory activity of an alcoholic extract of <italic>Quassia amara</italic> on production of LPS-stimulated pro-inflammatory mediators in J774 murine macrophages. Interestingly, the concentration of quassia extract used in their work was the same (10% wt/vol) as the concentration used in this study.</p>
<p>Among the pro-inflammatory mediators screened in this study, quassia extract displayed a potent inhibitory activity (3.98-fold, <italic>P</italic> &lt; .01) on TNF-ά, on IL-1ß (2.25-fold, <italic>P</italic> &lt; .01), and most interestingly on nitric oxide production (5.10-fold, <italic>P</italic> &lt; .01), the increased production of which is known to increase vasodilation.<sup><xref ref-type="bibr" rid="bibr12-0091270010391533">12</xref></sup></p>
<p>In another study, natural triterpenoids (the major active constituents of <italic>Quassia amara</italic> extract) were recently shown to alleviate skin inflammation in a mouse model of psoriasis.<sup><xref ref-type="bibr" rid="bibr13-0091270010391533">13</xref></sup> No comparison was made between current rosacea treatment and quassia extract. This may be the subject of future investigations.</p>
<p>In conclusion, it appears that topical quassia extract may represent a new, safe, and effective weapon in our armamentarium for the management of rosacea. Based on this encouraging evaluation, additional clinical trials involving larger groups of patients and employing double-blind, placebo protocols may be warranted.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010391533">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilkin</surname><given-names>JK</given-names></name>
<name><surname>Dahl</surname><given-names>M</given-names></name>
<name><surname>Detmar</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea</article-title>. <source>J Am Acad Dermatol</source>. <year>2002</year>;<volume>46</volume>:<fpage>584</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010391533">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>MV</given-names></name>
</person-group>. <article-title>Pathogenesis of rosacea</article-title>. <source>Adv Dermatol</source>. <year>2001</year>;<volume>17</volume>:<fpage>29</fpage>-<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010391533">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crawford</surname><given-names>GH</given-names></name>
<name><surname>Pelle</surname><given-names>MT</given-names></name>
<name><surname>James</surname><given-names>WD</given-names></name>
</person-group>. <article-title>Rosacea, 1: etiology, pathogenesis and subtype classification</article-title>. <source>J Am Acad Dermatol</source>. <year>2004</year>;<volume>51</volume>:<fpage>327</fpage>-<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010391533">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gomaa</surname><given-names>AH</given-names></name>
<name><surname>Yaar</surname><given-names>M</given-names></name>
<name><surname>Eyada</surname><given-names>MM</given-names></name>
<name><surname>Bhawan</surname><given-names>J</given-names></name>
</person-group>. <article-title>Lymphangiogenesis and angiogenesis in nonphymatous rosacea</article-title>. <source>J Cutan Pathol</source>. <year>2007</year>;<volume>34</volume>(<issue>10</issue>):<fpage>748</fpage>-<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010391533">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonamigo</surname><given-names>RR</given-names></name>
<name><surname>Bakos</surname><given-names>L</given-names></name>
<name><surname>Edelweiss</surname><given-names>M</given-names></name>
<name><surname>Cartell</surname><given-names>A</given-names></name>
</person-group>. <article-title>Could matriz-metalloproteinase-9 be a link between Demodex folliculorum and rosacea?</article-title> <source>J Eur Acad Dermatol Venereol</source>. <year>2005</year>;<volume>19</volume>(<issue>5</issue>):<fpage>646</fpage>-<lpage>647</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010391533">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>D</given-names></name>
</person-group>. <article-title>Reactive oxygen species and rosacea</article-title>. <source>Cutis</source>. <year>2004</year>;<volume>74</volume>(<issue>3 suppl</issue>):<fpage>17</fpage>-<lpage>20</lpage>, <fpage>32</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010391533">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>O</given-names></name>
<name><surname>Nielsen</surname><given-names>AO</given-names></name>
<name><surname>Bjerregaard</surname><given-names>P</given-names></name>
</person-group>. <article-title>Pediculosis capitis treated with Quassia tincture</article-title>. <source>Acta Derm Venereol</source>. <year>1978</year>;<volume>58</volume>(<issue>6</issue>):<fpage>557</fpage>-<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010391533">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ninci</surname><given-names>ME</given-names></name>
</person-group>. <article-title>Prophylaxis and treatment of pediculosis with Quassia amarga.</article-title> <source>Rev Fac Cien Med Univ Nac Cordoba</source>. <year>1991</year>;<volume>49</volume>(<issue>2</issue>):<fpage>27</fpage>-<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010391533">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toma</surname><given-names>W</given-names></name>
<name><surname>Gracioso</surname><given-names>JS</given-names></name>
<name><surname>Hiruma-Lima</surname><given-names>CA</given-names></name>
<name><surname>Andrade</surname><given-names>FDP</given-names></name>
<name><surname>Vilegas</surname><given-names>W</given-names></name>
<name><surname>Souza Brito</surname><given-names>ARM</given-names></name>
</person-group>. <article-title>Evaluation of the analgesic and antiedematogenic activities of Quassia amara bark extract</article-title>. <source>J Ethnopharmacol</source>. <year>2003</year>;<volume>85</volume>:<fpage>19</fpage>-<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010391533">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>H</given-names></name>
<name><surname>Lee</surname><given-names>KH</given-names></name>
<name><surname>Imakura</surname><given-names>Y</given-names></name>
<name><surname>Okano</surname><given-names>M</given-names></name>
</person-group>. <article-title>Anti-inflammatory agents III: structure-activity relationships of brusatol and related quassinoids</article-title>. <source>J Pharm Sci</source>. <year>1983</year>;<volume>72</volume>(<issue>11</issue>):<fpage>1282</fpage>-<lpage>1284</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010391533">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verma</surname><given-names>N</given-names></name>
<name><surname>Tripathi</surname><given-names>SK</given-names></name>
<name><surname>Sahu</surname><given-names>D</given-names></name>
<name><surname>Das</surname><given-names>HR</given-names></name>
<name><surname>Das</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Evaluation of inhibitory activities of plant extracts on production of LPS-stimulated pro-inflammatory mediators in J774 murine macrophages</article-title>. <source>Mol Cell Biochem</source>. <year>2010</year>;<volume>336</volume>(<issue>1-2</issue>):<fpage>127</fpage>-<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010391533">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amin</surname><given-names>AR</given-names></name>
<name><surname>Attur</surname><given-names>MG</given-names></name>
<name><surname>Thakker</surname><given-names>GD</given-names></name>
</person-group>. <article-title>A novel mechanism of action of tetracyclines: effects on nitric oxide synthases</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>;<volume>93</volume>:<fpage>14014</fpage>-<lpage>14019</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010391533">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Syrovets</surname><given-names>T</given-names></name>
<name><surname>Kess</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Targeting NF-kB with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis</article-title>. <source>J Immunol</source>. <year>2009</year>;<volume>183</volume>:<fpage>4755</fpage>-<lpage>4763</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>